Pediatric Immunization

The 2025 measles outbreak in Texas has reignited discussion surrounding vaccine-preventable diseases and the importance of maintaining high immunization rates.

A rural west Texas "undervaccinated" Mennonite community is the epicenter of the worst measles outbreak in the state in 30 years, the state health department reported.

A case of measles is a very rare diagnosis in the 21st century, but as MMR vaccination rates fall, the cases climb. Would you recognize the signs & symptoms?

Here, the 5 key signs and symptoms that characterize measles in the order of appearance.

Clesrovimab, if approved, would be the only immunization for both healthy and at risk infants using the same dose. FDA set A PDUFA date of June 2025.

Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.

HPV series initiation and completion was lower among adolescents seen at public vs private care settings and so was clinician guidance on vaccination in a new study.

A new study shows that higher vaccination rates were associated with a decrease in the prevalence of parent-reported asthma symptoms in children.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.